

Subject: New Generic Hepatitis C Medications

Beginning in January 2019, the manufacturer Gilead Sciences intends to sell new generics of their hepatitis C drugs Harvoni® and Epclusa® through a new subsidiary, Asegua Therapeutics.¹

This release comes after increased scrutiny and criticism from both patients and officials for the high cost associated with medications used in the treatment and cure of chronic diseases. The release of these generics is expected to provide savings and better access to hepatitis C medications through workers' compensation and other health plans such as Medicaid. In addition, it may potentially pave the way for new, long-term cost planning.

The Impact

At this time, First Script shows little to no impact for these medications.

For more information, please contact your Account Manager or Account Pharmacist.

1. <https://www.biopharmadive.com/news/gilead-creates-subsiary-to-sell-generic-versions-of-hep-c-blockbusters/533134/>